Menu
“We must stop abuses of the 340B program by covered entities who put profits before patients,” PhRMA spokesperson Nicole Longo says in the association's blog. | Shutterstock

PhRMA: Providers Use 340B as “Slush Fund”

In Pharma Industry Tom Mirga
The 340B program “attracts hospitals, clinics and for-profit pharmacies because it is easy for them to use the program as a slush fund to benefit their bottom lines, diverting money that could be used to help patients get better care and afford their medicines,” Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Director of Public Affairs Nicole Longo wrote yesterday in the association’s blog.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.